Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Jonathan W. Riess, Luis Paz‐Ares et al.|Lung Cancer|2022Cited by 7